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Serotonin transporter clustering 
in blood lymphocytes predicts the outcome 
on anhedonia scores in naïve depressive 
patients treated with antidepressant medication
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Abstract 
Background: We have shown that serotonin transporter (SERT) clustering in blood lymphocytes is altered in major 
depression and correlates with pharmacological therapeutic responses measured with the Hamilton scale. In the 
present report, we extend these results to the self‑assessment anhedonia scale, as anhedonia is a cardinal symptom of 
major depression that is difficult to treat with first‑line antidepressants.
Methods: We collected blood samples from 38 untreated depression patients at the time of enrolment and 8 weeks 
after pharmacological treatment. We used the self‑assessment anhedonia scale to evaluate anhedonia symptoms 
before and after treatment. We also used quantitative immunocytochemistry to measure SERT clusters in blood 
lymphocytes.
Results: Evaluation of the distribution of SERT clusters size in the plasma membrane of lymphocytes identified 
two subpopulations of naive depression patients: Depression I (D‑I) and Depression II (D‑II). While naïve D‑I and D‑II 
patients initially showed similar anhedonia scores, D‑II patients showed a good response in anhedonia symptoms 
after 8 weeks of psychopharmacological treatment, whereas D‑I patients failed to show any improvement. Psychop‑
harmacological treatment also induced an increase in the number of SERT clusters in lymphocytes in the D‑II group, 
and this increase correlated with the improvement in anhedonia symptoms.
Conclusions: SERT clustering in peripheral lymphocytes can be used to identify patient response to antidepressant 
therapy as ascertained by anhedonia scores.
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Background
Major depression is a severe psychiatric disorder char-
acterized by depressed mood, diminished interest or 
pleasure in most daily activities (anhedonia), fatigue, psy-
chomotor agitation, and suicidal behavior [1, 2]. Major 
depressive disorder also increases the risk of suicidal 
ideation, attempted suicide and death by completed 
suicide. The World Health Organization has further 
reported that suicide attempts are up to 20 times more 
frequent than completed suicides and that mental health 
disorders (particularly depression and substance abuse) 
are associated with more than 90 % of all cases of suicide 
[3].
Individuals suffering from depression have increased 
medical comorbidities and decreased social roles [4]. 
Although numerous antidepressants have been devel-
oped, about one-third of patients are non-responders 
to these medications [5, 6], and recent meta-analyses 
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suggest that up to 2/3 of patients do not reach remis-
sion [7–9]. Therefore, there is interest in identifying bio-
markers of therapeutic efficacy, which could significantly 
advance the development of personalized medical treat-
ment for depression patients [10].
In two recent papers, we have shown that the pat-
tern of clustering of two proteins (the serotonin trans-
porter -SERT- and the serotonin 2A receptor -5HT2A-) 
in the plasma membrane of peripheral lymphocytes can 
differentiate two subpopulations of naïve depression 
patients that show a differential response to antidepres-
sant treatment [11, 12]. We ascertained the efficacy of 
the treatment by evaluating patient scores on the Ham-
ilton depression rating scale (HDRS) [13]. However, the 
use of this scale has some limitations, because it does not 
properly evaluate some relevant symptoms in depres-
sion, such as anhedonia [14, 15]. Not only is anhedonia 
a key symptom of depression, but it also seems to be 
particularly difficult to treat with first-line antidepres-
sant drug therapies [16–18], and its presence may repre-
sent a predictor of poor treatment response [19]. In fact, 
anhedonia is considered to be one of the most promis-
ing endophenotypes of depression [reviewed in 20]. One 
of us has proposed that the concept of anhedonia could 
describe a final common pathway within which differ-
ent phenomena converge (i.e., the so-called anhedonia of 
schizophrenia would be a different phenomenon than the 
“true anhedonia” characteristic of depression) [15]. From 
this idea, a novel anhedonia rating scale called the self-
assessment anhedonia scale (SAAS) was developed [21].
In this report, we evaluate alterations in the expression 
of SERT protein clustering in lymphocytes with respect 
to the scores in the SAAS anhedonia scale in a popula-
tion of initially drug naïve depression patients (to avoid 
any misunderstanding, from here on we use the term 
depression Total, DT, to refer to the total sample of naïve 
patients enrolled in the study (n =  38), and Depression 
I (D-I) and Depression II (D-II) to refer to the two sub-
populations) [11]. We hypothesized that the pattern of 
membrane protein clustering in blood lymphocytes will 
differentiate between naïve depression patients who 
respond to antidepressant treatment and naïve depres-
sion patients who do not respond to antidepressant treat-
ment, as measured by changes in SAAS scores before and 
after treatment. This study will allow us to define SERT 
clustering in lymphocytes as a promising candidate bio-
marker of specific anhedonia symptoms and of their 
response to antidepressant treatment.
Methods
Subjects
This study used the same group of participants [major 
depression patients (n =  38)] who were involved in our 
two recent studies on membrane protein clustering and 
HDRS scores in major depression patients [11, 12] (see 
Table  1). This study is in compliance with the Code of 
Ethics of the World Medical Association (Declaration of 
Helsinki), and was approved by the Rebullon Hospital 
ethics committee, which required the signing of a writ-
ten informed consent from all participants. The inclu-
sion criteria for the depression group required (a) be at 
least 18-year old; (b) meet DSM-IV-TR criteria for major 
depression; (c) have a minimum score of 16 points on the 
HDRS; (d) present with no other major psychiatric disor-
der or somatic illness; and (e) be naïve for antidepressant 
treatment at the beginning of the study. Not being a clini-
cal trial, the psychiatrists treated the patients with the 
antidepressant medication that they deemed necessary, 
although most patients received an antidepressant and an 
anxiolytic (for details, please see Reference [11]).
Scoring of clinical scales
A clinical psychologist (blind to the diagnosis and drugs 
prescribed) collected the demographic data of patients 
and clinical scores. The SAAS scale was used to assess 
the severity of anhedonia symptoms in depression before 
and after 8  weeks of pharmacological treatment. The 
SAAS is a 27-item scale that scores the “intensity” and 
Table 1 Sociodemographic characterization of the depres-
sion group
Depression
Number 38
Age 42.25 ± 2.42
Gender
 Men 15 (39 %)
 Women 23 (61 %)
Education
 Primary 20 (52.6 %)
 Secondary 12 (28.8 %)
 Graduation 6 (18.6 %)
Socioeconomic status
 High 1 (2 %)
 Average 30 (79 %)
 Low 7 (19 %)
Residence
 Urban 30 (73 %)
 Rural 10 (27 %)
Marital status
 Single 6 (17 %)
 Married 20 (52 %)
 Separated 6 (15 %)
 Divorced 3 (8 %)
 Widowed 3 (8 %)
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“frequency” of specific anhedonia symptoms, as well as 
the “changes” in those symptoms as perceived by the 
patient. It also discriminates between items related to 
“physical,” “intellectual,” or “social” enjoyment [22]. After 
the patients completed the scales, the clinical psycholo-
gist calculated the overall score and the scores on the 
“intensity,” “frequency,” “change,” “physical,” “intellectual,” 
and “social” subscales.
We have used the SAAS scale instead of other widely 
used scales such as the Physical (PAS) and Social Anhe-
donia (SAS) Scale [21] or the Snaith-Hamilton pleasure 
scale (SHAPS) [24, 25] because anhedonia rating scales 
published to date fail to distinguish between the differ-
ent subtypes of anhedonia [26]. The validity and reliabil-
ity of these scales have not been adequately established 
in MDD patients [27–29], and there is a marked overlap 
between schizophrenic patients and controls on PAS 
scores [30]. In addition, all these scales unanimously 
emphasize the experience of pleasure in response to posi-
tive stimuli, with little or no attention to diminished drive 
or motivation, not being capable of measuring the per-
ception of change in the hedonic capacity of the patient 
[22]. We identified response as a significant improvement 
in SAAS scale upon pharmacological treatment, if was 
accompanied of a 50  % decrease in scores in HDRS as 
evaluated in our previous study using the same patients 
[11].
Drawing of blood samples and isolation of lymphocytes
Blood samples were drawn by a trained nurse both at 
baseline and 8  weeks after pharmacological treatment. 
Briefly, blood samples were drawn with a BD Vacutainer 
glass whole blood tube, containing 1.5 ml ADC solution 
[A-trisodium citrate (22 g/l), citric acid (8 g/l), and dex-
trose (24.5 g/l)]. We collected three tubes of blood from 
each patient. Lymphocytes were isolated after centrifuga-
tion in Ficoll-Paque Plus, and subsequently washed and 
re-centrifuged to remove contaminating platelets (for 
details, see Rivera-Baltanas et al. 2010). Lymphocyte pel-
lets were fixed for one minute in a solution of 1 % para-
formaldehyde in phosphate buffer, and maintained for up 
to 10 days in the fridge (4 °C) before processing for SERT 
immunocytochemistry.
Immunocytochemistry
Immunolabeling of the serotonin transporter (SERT) 
was done by successive centrifugation and re-suspension 
steps as explained by Rivera-Baltanas et  al. [23]. After 
washing in PBS, lymphocytes were incubated with a solu-
tion of human IgG (6:100) in 1  % BSA in PBS to block 
membrane immunoglobulins. Thereafter, samples were 
incubated overnight at 4 °C with a solution containing a 
rabbit anti human SERT antibody (Millipore, AB9322) 
diluted 1:100 in 1  % BSA in PBS. We have previously 
characterized this antibody by Western blot [11]. After-
ward, the samples were washed in PBS and incubated in 
the dark at RT for 1  h with a goat anti-rabbit antibody 
conjugated with Alexa Fluor 488 (Molecular Probes, 
A11008) diluted 1:200 in 1 % BSA in PBS. After immu-
nolabeling, samples were collected onto Superfrost (+) 
microscope slides (Fisher Scientific) and mounted with 
Moviol anti-fading medium (Calbiochem) before being 
cover-slipped. Samples were maintained in the dark at 
−20 °C until observation in a confocal microscope.
Imaging
Immunolabeling of SERT was observed on a spectral 
confocal microscope (Leica TCS-SP2). We obtained 
images from 100 lymphocytes per sample. The images 
were analyzed using the imaging software Image J 1.42 
(NIH), which allows for automatic counting of the num-
ber of SERT clusters per lymphocyte as well as a calcula-
tion of the size of each SERT cluster (see Fig. 1).
Statistical analyses
All statistical analyses were conducted using IBM’s Sta-
tistical Package for the Social Sciences (SPSS v. 20). Two-
way ANOVAs (with treatment time -before/after- and 
drug treatment as the two variables) were used to explore 
statistical differences in SAAS scores upon medication 
with different classes of drugs (i.e., antidepressants only, 
antidepressant plus anxiolytic, antidepressant plus mood 
stabilizer, or antidepressant plus antipsychotic). The dif-
ference in scores SAAS associated with the type of treat-
ment is not our main study variable, but we analyzed 
the effect of type of antidepressant treatment to know 
if treatment was conditioned the SAAS scores, so we 
could consider a variable that could be interfering with 
the interpretation of our results. We used paired sam-
ples t-tests to analyze treatment effects on clinical scales 
or SERT clustering within each depression group, and 
one-way ANOVAs followed by post hoc Bonferroni tests 
to examine differences among groups after treatment. 
Finally, we carried out one-way ANOVAs to evaluate 
differences in the possible correlation (analyzed by Pear-
son’s correlation) between improvement in SAAS scores 
with treatment, and the increase in the number of SERT 
clusters induced by treatment. The criterion for statistical 
significance was set at p < 0.05 for all analyses. All graphs 
depict the mean ± SEM.
Results and discussion
Demographic characterization of the subjects
The cohort of depression patients analyzed in this 
study is the same as the cohort we used in two recent 
reports on membrane protein clustering of SERT and 
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5-HT2A receptors [11, 12]. Almost two-thirds of the 
patients were women, reflecting the epidemiological 
data showing a higher degree of depression incidence 
in women compared to men (Table  1). Not being a 
clinical trial, the patients were prescribed the medi-
cation that the psychiatrists felt was the best for each 
case. However, there were no significant differences 
in the therapeutic outcome depending on the class 
of drugs prescribed (for details, please see reference 
[11]).
Analysis of SERT clusters in lymphocytes from depression 
patients
Figure  1a, b shows an example of SERT labeling in 
the plasma membrane of lymphocytes in D-I and D-II 
depression subgroups. The present study includes 
the same patients than in our previous study of SERT 
clusters in depression in relation to alterations in the 
Hamilton scale [11] where we identified these two sub-
groups based on differences in the distribution of SERT 
clusters size (an example of the different SERT clusters 
size distribution in D-I and D-II patients is shown in 
Fig. 1c, d).
Analysis of SAAS scores evidences no differences 
between D‑I and D‑II naïve depression patients, 
but significant improvement upon treatment only in D‑II 
patients
Table  2 shows the SAAS scores and the scores for the 
different anhedonia subscales (intensity, frequency and 
change of symptoms, or items related to physical, intel-
lectual, or social anhedonia). There were no statisti-
cally significant differences between D-I and D-II naïve 
patients in any of the scores (before treatment). However, 
after 8 weeks of pharmacological treatment, there was a 
significant improvement in anhedonia symptoms within 
the D-II group only (Tables  2, 3; Fig.  2). Specifically, 
patients in the D-II group showed a decrease of 47  % 
in SAAS scores, and also significant decreases in all the 
subscales (61 % decrease in Intensity, 46 % in Frequency, 
37 % in Change, 49 % in physical anhedonia symptoms, 
52 % in intellectual symptoms, and 34 % in social symp-
toms). In fact, the D-I group patients not only failed to 
show improvement in anhedonia symptoms after treat-
ment, but their overall anhedonia scores after treatment 
also showed a tendency to be higher than before treat-
ment (Table  2). In addition, although the SAAS scores 
Fig. 1 Serotonin transporter (SERT) immunostaining in blood peripheral lymphocytes. SERT labeling is evidenced as immunofluorescent clusters 
on the plasma membrane of lymphocytes from D‑I (a) and D‑II (b) depression patients. The two subgroups of naïve depression patients are differ‑
entiated by a different distribution of SERT clusters size, with patients in the D‑I group having a modal peak of almost 40 % of SERT clusters between 
0.05 and 0.10 μm2 (c), while this peak is much less evident in patients from the D‑II group (d). For more details, see references [11, 12]
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in the D-I and D-II groups in naïve patients were similar, 
there were significant group differences after treatment, 
with the D-II group showing lower levels of anhedo-
nia as measured by SAAS scores (Table 2; Fig. 2). SAAS 
scores after treatment were 53 % lower in the D-II than 
in the D-I group, and they also were lower for the sub-
scales (66 % lower in Intensity, 58 % in Frequency, 39 % in 
Change, 66 % in physical symptoms, 55 % in intellectual 
symptoms, and 41 % in social symptoms).
Improvement in SAAS scores after pharmacological 
treatment in D‑II patients correlates with the increase 
in the number of SERT clusters in lymphocytes
As shown in Table 4, there is a negative correlation (i.e., a 
decrease in anhedonia scores correlates with an increase 
in the number of SERT clusters per lymphocyte) that is 
observed for SAAS and all the subscales, with the excep-
tion of the subscale measuring the change in preferences 
(one of the subscales where D-II patients show a rela-
tively low improvement, see Table 2).
Discussion
The main finding observed in this study is that upon 
8  weeks of pharmacological treatment, patients within 
the D-II depression subgroup show a good response (evi-
denced by significant improvement of anhedonia symp-
toms as scored by the SAAS scale), whereas D-I patients 
fail to show any improvement in anhedonia symptoms. In 
addition, we also demonstrate that this effect is observed 
for all the SAAS subscales, and that the improvement in 
anhedonia symptoms in the D-II group correlates with the 
level of increase in the number of SERT clusters within 
the membrane of peripheral lymphocytes after pharmaco-
logical treatment. These results are primarily discussed in 
the following paragraphs in relation to the possible clini-
cal importance of the application of anhedonia clinical 
scales and analysis of SERT clustering in lymphocytes to 
evaluate major depression prognosis and therapeutic effi-
cacy of antidepressant treatment in individual patients.
In two recent reports, we have analyzed the varia-
tions in membrane protein clustering in lymphocytes 
in depression of two serotonergic markers (SERT and 
the 5-HT2A receptor), and demonstrated the existence 
of two subpopulations of naïve depression patients D-I 
and D-II. Lymphocytes from D-I patients have about 
40  % of SERT/5-HT2A clusters within the modal peak 
of 0.05–0.10  μm2 in size, whereas in lymphocytes from 
D-II patients, only about 25 % of SERT/5-HT2A clusters 
fall into this category [11, 12]. Following this categoriza-
tion, the naïve depression patients were assigned to the 
D-I or D-II groups (30 patients were observed as D-I and 
8 patients as D-II). These two subpopulations are dis-
tinguished by the distribution of receptor clusters size, 
despite showing similar scores on the HDRS [11, 12]. In 
the present report, we used a similar approach (as the 
depression cohort is the same one used in our previ-
ous studies) and evidence that scores in the SAAS scale 
are also similar between D-I and D-II naïve depression 
groups.
Table 2 Analysis of SAAS scores before and after treatment
DT depression total (n = 38), D‑I depression I (n = 30), D‑II depression II (n = 8)
Before treatment After treatment
DT D‑I D‑II DT D‑I D‑II
SAAS 287.37 ± 24.7 291.85 ± 2946 272.25 ± 47.58 285.40 ± 31.56 312.26 ± 33.74 145.40 ± 45.98
Intensity 87.46 ± 8.85 89.70 ± 10.6 79.87 ± 15.6 84.71 ± 10.44 94.78 ± 11.58 31.40 ± 10.33
Frequency 87.34 ± 9.1 90.01 ± 10.8 78.35 ± 16.5 89.07 ± 9.88 99.44 ± 10.57 41.98 ± 13.5
Change 112.57 ± 9.2 112.14 ± 10.81 114.03 ± 20.11 111.6 ± 10.67 118.04 ± 11.45 72.02 ± 20.38
Physical 114.50 ± 10.54 116.50 ± 12.59 111.00 ± 19.42 118 ± 13.03 130.28 ± 13.90 57 ± 21.58
Intellectual 102.17 ± 9.96 102.81 ± 12.17 100.13 ± 16.36 98.02 ± 12.52 107.2 ± 13.98 48.5 ± 1347
Social 67.74 ± 7.23 68.69 ± 8.49 64.64 ± 14.51 68.78 ± 7.02 72.21 ± 7.79 42.91 ± 22.21
Table 3 Analysis of  SAAS scores before  and after  treat-
ment
Depression total Depression I Depression II
SAAS t(37) = 1.226; 
p > 236
t(29) = −0.210: 
p > .836
t(7) = 3.054; 
p < .002
Intensity t(37) = 1.176; 
p > 211
t(29) = −0.036: 
p > .972
t(7) = 3.113; 
p < .002
Frequency t(37) = 1.055; 
p > .284
t(29) = −0.275: 
p > .786
t(7) = 2.449; 
p < .04
Change t(37) = 1.062; 
p > .296
t(29) = −0.279: 
p > 783
t(7) = 2.543; 
p < .04
Physical t(37) = 1.009; 
p > 320
t(29) = −0.437: 
p > 665
t(7) = 2.91; p < .02
Intellectual t(37) = 1.343; 
p > 189
t(29) = −0.059: 
p > 953
t(7) = 3.44; p < .01
Social t(37) = 1.116; 
p > 271
t(29) = −0.037: 
p > 970
t(7) = 2.38; p < .05
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Interestingly, our previous study of SERT clusters in 
depression demonstrated that although patients in both 
the D-I and D-II groups showed a significant response 
after 8  weeks of pharmacological treatment (as meas-
ured by the HDRS), the patients in the D-II group 
showed a better response than those in the D-I group, 
with ¾ of D-II patients showing remission of symptoms 
[11]. Assessment of SAAS scores also indicates that 
D-II group patients show a significant improvement in 
anhedonia symptoms after pharmacological treatment; 
however—differently than the observations in HDRS 
scores—patients in the D-I group showed no signifi-
cant improvement in anhedonia symptoms, and in fact 
they showed a tendency to an increase in SAAS scores 
(see Table  2). This implies that analysis of membrane 
protein clustering of SERT and/or 5-HT2A (as the D-I 
and D-II depression subpopulations have been equally 
demonstrated by employing any of those markers as 
Fig. 2 Histograms depicting the variation in the self‑assessment anhedonia scale (SAAS) and the different subscales in the D‑I and D‑II depression 
groups after psychopharmacological treatment. For details on the SAAS scale, see Ref. [22]
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we previously have shown [11, 12]), identifies two sub-
populations of naïve depression patients, one of which 
(the D-II group) shows a good improvement in anhedo-
nia symptoms upon pharmacological treatment, while 
the other group (i.e., D-I) fails to show any response. 
One should, therefore, consider the possibility of using 
the analysis of serotonergic membrane protein cluster-
ing in lymphocytes as a way to identify naïve depressive 
patients that will show a good or bad response to con-
ventional antidepressant medication as assessed by the 
measurement of anhedonia symptoms.
Improvement of anhedonia symptoms in D-II patients 
is observed not only in the general SAAS scores, but also 
in all the subscales, albeit the highest improvement is 
found in the score on intensity of symptoms, and in the 
intellectual and physical anhedonia symptoms, whereas 
for D-I patients, they fail to improve not only in general 
SAAS scores but also in all the subscales. These find-
ings reinforce our previous suggestion that the pattern 
of membrane protein clustering could be used to iden-
tify patients who will show a good or bad therapeutic 
response to antidepressant medication.
When analyzing the alterations in SERT cluster-
ing in lymphocytes after pharmacological treatment, 
we found a 27  % increase in the number of SERT clus-
ters per lymphocyte only in D-II patients. Therefore, we 
wanted to analyze if the improvement in SAAS scores in 
D-II patients correlates with an increase in SERT num-
bers. As shown in Table 4, there is a negative correlation 
(i.e., a decrease in anhedonia scores correlates with an 
increase in the number of SERT clusters per lymphocyte) 
that is observed for SAAS and all the subscales, with the 
exception of the subscale measuring the change in pref-
erences (one of the subscales where D-II patients show 
a relatively low improvement, see Table  2). We do not 
know the possible consequences for lymphocytes physi-
ology of an increase in the number of SERT clusters, but 
it is of interest to note that an increase in interleukin 2, a 
cytokine primarily released by T lymphocytes in periph-
ery (and also expressed in CNS) is known to have an 
effect on anhedonia behavior [31].
It will be necessary to perform additional studies to 
understand the implications of alterations in membrane 
protein clustering in lymphocytes on the secretion of 
cytokines, and to perform a clinical trial to properly 
confirm the findings of this report, but one could sur-
mise the possibility that patients in the D-I group (that 
would respond poorly to conventional antidepressant 
treatment as ascertained by measurement of anhedonia 
symptoms) could be prescribed unconventional anti-
depressants like bupropion [32] or agomelatine [33, 34] 
from the start. In addition, it should be logical to study 
the possible use of the increase in SERT clusters on lym-
phocyte cell membranes as a possible surrogate marker 
of antidepressant efficacy, during the development of 
new antidepressants.
Limitations
The small sample size may have weakened the power of 
statistical analyses. This is not a controlled clinical trial, 
each patient received treatment following clinical prac-
tice, mainly the combination of an antidepressant with 
an anxiolytic treatment. The present study should be fol-
lowed by a proper double-blind controlled clinical trial to 
validate the data.
The study is based on the principles of a new paradigm 
and a new scale of anhedonia which has no other compa-
rable instrument as a gold standard.
Conclusions
We have shown that analysis of membrane protein clus-
tering in peripheral lymphocytes can be used to identify 
subgroups of naïve depression patients that show a dif-
ferent outcome in anhedonia symptoms after antidepres-
sant treatment. We suggest that analysis of membrane 
protein clustering could be a promising candidate used as 
a biomarker of therapeutic efficacy in anhedonia symp-
toms for patient stratification in clinical trials.
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